Clinical "Cytokine Storm" as Revealed by Monocyte Intracellular Flow Cytometry: Correlation of Tumor Necrosis Factor α With Severe Gut Graft-Versus-Host Disease

被引:40
作者
Fowler, Daniel H. [1 ]
Foley, Jason [1 ]
Hou, Jeannie Whit-Shan [1 ]
Odom, Jeanne [1 ]
Castro, Kate [1 ]
Steinberg, Seth M. [2 ]
Gea-Banacloche, Juan [1 ]
Kasten-Sportes, Claude [1 ]
Gress, Ronald E. [1 ]
Bishop, Michael R. [1 ]
机构
[1] NCI, Dept Expt Transplantat & Immunol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1542-3565(04)00011-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Gut graft-versus-host disease (GVHD) contributes significantly to lethality after allogeneic hematopoietic stem-cell transplantation (HSCT). In murine models, macrophage secretion of interleukin 1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF-alpha) contributes to gut GVHD pathogenesis. To help characterize whether human gut GVHD has similar biological characteristics, monocyte IL-1 alpha and TNF-alpha production were evaluated after HSCT. Methods: Patients withrefractory hematologic malignancy (n = 17) underwent reduced-intensity conditioning, HLA-matched sibling HSCT, and cyclosporine A GVHD prophylaxis. After HSCT, monocyte IL-1 alpha and TNF-alpha levels were measured using intracellular flow cytometry (IC-FCM), and results were correlated with clinical GVHD. Results: Incidences of acute GVHD were none (n = 3), grades I-II (n = 9), or grades III-IV (n = 5; each case with stage 2-3 gut GVHD). Posttransplantation monocyte IL-1 alpha production (percentage of CD14(+) IL-1(+) cells) increased significantly from 8.7% +/- 3.7% (week 2) to 40.3% +/- 7.3% (week 4; P = 0.0065) and was not associated with GVHD severity (P = 1.00). Conversely, increases in monocyte TNF-alpha were quantitatively reduced and temporally delayed, from 0.6% +/- 0.2% (week 2) to 3.6% +/- 1.4% (week 6; P = 0.076). Most importantly, elevation of monocyte TNF-alpha level correlated with increased gut GVHD severity (P = 0.0041); increases in monocyte TNF-alpha levels typically preceded the onset of gut GVHD symptoms. Conclusions: Human gut GVHD after reduced-intensity allogeneic HSCT is associated with monocyte cytokine secretion initially involving IL-1 alpha, followed by TNF-alpha. Serial measurement of monocyte cytokines, in particular, TNF-alpha, by IC-FCM may represent a noninvasive method for GVHD monitoring, potentially allowing the identification of patients appropriate for early-intervention strategies.
引用
收藏
页码:237 / 245
页数:9
相关论文
共 48 条
[1]   Plasma cytokines in graft vs host disease and complications following bone marrow transplantation [J].
Abdallah, AN ;
Boiron, JM ;
Attia, Y ;
Cassaigne, A ;
Reiffers, J ;
Iron, A .
HEMATOLOGY AND CELL THERAPY, 1997, 39 (01) :27-32
[2]  
Agresti A., 1990, CATEGORICAL DATA ANA, P79
[3]   Etanercept in graft-versus-host disease [J].
Andolina, M ;
Rabusin, M ;
Maximova, N ;
Di Leo, G .
BONE MARROW TRANSPLANTATION, 2000, 26 (08) :929-929
[4]  
[Anonymous], NONPARAMETRIC STAT M
[5]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE [J].
ANTIN, JH ;
WEINSTEIN, HJ ;
GUINAN, EC ;
MCCARTHY, P ;
BIERER, BE ;
GILLILAND, DG ;
PARSONS, SK ;
BALLEN, KK ;
RIMM, IJ ;
FALZARANO, G ;
BLOEDOW, DC ;
ABATE, L ;
LEBSACK, M ;
BURAKOFF, SJ ;
FERRARA, JLM .
BLOOD, 1994, 84 (04) :1342-1348
[6]   Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation [J].
Antin, JH ;
Weisdorf, D ;
Neuberg, D ;
Nicklow, R ;
Clouthier, S ;
Lee, SJ ;
Alyea, E ;
McGarigle, C ;
Blazar, BR ;
Sonis, S ;
Soiffer, RJ ;
Ferrara, JLM .
BLOOD, 2002, 100 (10) :3479-3483
[7]   The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice [J].
Baker, MB ;
Altman, NH ;
Podack, ER ;
Levy, RB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2645-2656
[8]   Measurement of serum cytokines [J].
Barnes, A .
LANCET, 1998, 352 (9124) :324-325
[9]   Non-myeloablative stem cell transplants [J].
Barrett, J ;
Childs, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :6-17
[10]   Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas [J].
Bishop, MR ;
Hou, JWS ;
Wilson, WH ;
Steinberg, SM ;
Odom, J ;
Castro, K ;
Kasten-Sportes, C ;
Gea-Banacloche, J ;
Marchigiani, D ;
Gress, R ;
Fowler, DH .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (03) :162-169